Autolus Therapeutics (NASDAQ:AUTL) Earns “Buy” Rating from HC Wainwright

Autolus Therapeutics (NASDAQ:AUTL)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a research note issued on Monday,Benzinga reports. They presently have a $10.00 price objective on the stock. HC Wainwright’s price objective would indicate a potential upside of 430.50% from the company’s previous close.

A number of other analysts also recently weighed in on AUTL. Needham & Company LLC reaffirmed a “buy” rating and set a $10.00 price target on shares of Autolus Therapeutics in a report on Thursday, April 9th. Wall Street Zen raised Autolus Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, June 13th. Jefferies Financial Group raised Autolus Therapeutics to a “strong-buy” rating in a research note on Monday, April 20th. Finally, Weiss Ratings cut Autolus Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday. Two analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $8.75.

Autolus Therapeutics Stock Performance

Shares of NASDAQ AUTL traded up $0.40 during trading hours on Monday, reaching $1.89. 11,228,035 shares of the stock were exchanged, compared to its average volume of 1,638,779. The firm has a market capitalization of $501.70 million, a price-to-earnings ratio of -1.73 and a beta of 2.04. The stock’s fifty day simple moving average is $1.57 and its 200 day simple moving average is $1.52. Autolus Therapeutics has a 52 week low of $1.18 and a 52 week high of $2.52.

Autolus Therapeutics (NASDAQ:AUTL) last released its quarterly earnings results on Friday, May 15th. The company reported ($0.27) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.29) by $0.02. Autolus Therapeutics had a negative return on equity of 128.59% and a negative net margin of 311.98%.The business had revenue of $26.22 million during the quarter, compared to the consensus estimate of $26.27 million. Research analysts predict that Autolus Therapeutics will post -0.95 EPS for the current fiscal year.

Institutional Trading of Autolus Therapeutics

Large investors have recently modified their holdings of the business. Marex Group plc purchased a new position in shares of Autolus Therapeutics during the second quarter valued at approximately $28,000. Independent Advisor Alliance purchased a new stake in Autolus Therapeutics in the fourth quarter worth about $28,000. GAMMA Investing LLC raised its stake in Autolus Therapeutics by 115.6% during the second quarter. GAMMA Investing LLC now owns 15,499 shares of the company’s stock valued at $25,000 after buying an additional 8,309 shares during the last quarter. SmartHarvest Portfolios LLC purchased a new stake in Autolus Therapeutics during the 4th quarter valued at about $43,000. Finally, Waverly Advisors LLC bought a new position in Autolus Therapeutics in the 1st quarter valued at approximately $37,000. 72.83% of the stock is owned by institutional investors.

Autolus Therapeutics Company Profile

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.